drugset / Trial / NCT02641301

Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects

NCT02641301

Phase 4 Unknown 24 enrolled Hopital Lariboisière
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this study is to determine whether sustained release morphine pharmacokinetics parameters in patients undergone roux-en-y gastric bypass (RYGB) differ from subjects who did not. Our hypothesis is that exposure is comparable. Indeed, in the Study OBEMO (Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass; NCT00943969) the investigators observed changes in pharmacokinetics parameters for immediate release morphine, probably due to an earlier absorption of the morphine, in agreement with the expected clinical effect of this formulation.

Timeline

Start
2015-12
Primary completion
2016-12
Completion
2017-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 30 mg Oral

Indications

No indication recorded.